The Readout Loud 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
19 snips
Jan 15, 2025 
Dave Ricks, CEO of Eli Lilly, shares insights from the J.P. Morgan Healthcare Conference. He discusses the challenges of pricing and accessing GLP-1 obesity medications, despite high demand. Ricks delves into the implications of the Inflation Reduction Act on drug pricing and regulatory hurdles. He emphasizes the importance of business relationships with the incoming Trump administration and aims for Eli Lilly to reach a trillion-dollar valuation in healthcare. The conversation also touches on significant biotech M&A activities and the evolving landscape of drug development.
AI Snips
Chapters
Transcript
Episode notes
IRA Negotiation Pause Request
- Lilly formally requests the Trump administration pause IRA negotiations due to concerns about implementation.
- Ricks believes the current structure is confusing and may not effectively lower costs for patients.
Potential Impact of Semaglutide Negotiation
- Ricks predicts potential market chaos and patient frustration if semaglutide's price is negotiated under current IRA rules.
- He suggests alternative solutions like a cap on out-of-pocket costs for negotiated drugs.
Conflicting Views in Trump Administration
- Ricks discusses conflicting viewpoints within the Trump administration regarding pharmaceutical companies and drug pricing.
- He hopes for a focus on making America healthy, aligning with his company's mission.